Frances Anastassacos
@fran_anastasBUILDING NABLA BIO.
Similar User
@glebkuz
@SurgeBiswas
@subaita_rahman
@nabsicle
@Jack_O_Meara
@DrSynbio
@Dyno_Tx
@lexrovner
@BigHatBio
@dbgoodman
@ekelsic
@omri_drory
@SeanRMcClain
@AvivSpinner
@ntilmans
Excited to share @nablabio is partnering with 3 of the world’s largest pharma cos to use integrated AI and wet-lab tech to design antibodies against challenging disease targets. Thrilled to also add @radicalvcfund who led our $26M Series A to the family! bit.ly/4dDk4lP
Tiny startup Nabla Bio posted a preprint Thursday highlighting its progress in creating antibodies from scratch that look therapeutically viable against some hard-to-drug targets in what it’s calling a first for the field. endpts.com/nabla-bio-move…
The @nablabio team has been quietly building the future of AI x Bio. Today they shared incredible de novo antibody design capabilities. Able to design antibodies with strong ✅ affinity ✅ developability ✅ function with success across a range of proteins.
Incredibly excited to share new results from Nabla Bio where we show we can design antibodies de novo for use in therapeutic discovery. We introduce JAM, an AI system we’ve developed to design de novo antibodies with good affinities, early stage developability, and function.…
Really nice complementary work to our computational solubilisation of GPCRs and Claudins! Glad our approach is inspiring further research into this topic. nature.com/articles/s4158…
Incredibly excited to share new results from Nabla Bio where we show we can design antibodies de novo for use in therapeutic discovery. We introduce JAM, an AI system we’ve developed to design de novo antibodies with good affinities, early stage developability, and function.…
Amazing work from @SurgeBiswas and the team at @NablaBio — the era of de novo drug design is HERE
Incredibly excited to share new results from Nabla Bio where we show we can design antibodies de novo for use in therapeutic discovery. We introduce JAM, an AI system we’ve developed to design de novo antibodies with good affinities, early stage developability, and function.…
We designed de novo VHH (nanobodies) to SARS-CoV-2 RBD. We saw a 0.6% success rate, and top designs had double-digit nM affinity and functionally neutralized pseudovirus with sub-nM IC50s. We found they showed good early stage developability profiles and were epitope specific.
Lastly, we used JAM to successfully generate antibodies against two difficult, insoluble, multipass membrane protein targets - Claudin-4 and a GPCR, CXCR7. We not only used JAM to generate antibodies, but also to generate solubilized proxies of these targets to facilitate…
Incredibly excited to share new results from Nabla Bio where we show we can design antibodies de novo for use in therapeutic discovery. We introduce JAM, an AI system we’ve developed to design de novo antibodies with good affinities, early stage developability, and function.…
“My hat is off to them for choosing targets well and not settling for a bunch of academic papers that settle five-decade-old challenges,” biologist George Church said. Nabla Bio moves closer to AI-created antibody drugs: endpts.com/nabla-bio-move…
Boom Capital is hiring a Chief of Staff. 🚀 This is one of our most important hires. You'll liaise with our in-house scientific society and impact every aspect of a VC firm, serving unprecedented ideas, scientists and engineers. Join boomcap.co and apply here:…
The topic on Infinite ML pod today is -- Designing antibodies with AI. We have @SurgeBiswas on the show to talk about it. He's the cofounder/CEO of Nabla Bio. They recently raised their $26M Series A led by @radicalvcfund In this clip, he talks about what goes into designing…
Seth Ela + 50Y were the first to believe in us and wrote us a 700k check in 2020 to get us started. That was first life for us. lucky to work with some of the most founder friendly & competent investors. They are also just good people
The team that invented protein LLMs has $26M more to continue advancing state of the art, and partnerships with AstraZeneca, Bristol Myers Squibb, and Takeda worth $550M+ in upfront and milestone payments + royalties. @fiftyyears led the pre-seed and supported every round since.
Reminder to check out @SurgeBiswas’s talk @PEGSboston later today!
I’m speaking today at @PEGSboston, 5:10 pm, Eng Antibodies. Talk will cover new “solMPMP” tech from @nablabio where we use generative ML to create soluble proxies of valuable multipass membrane protein drug targets, and use these proxies to facilitate design of new biologics.
Today we announce the close of a $26M Series A financing, led by @radicalvcfund with participation from all existing investors, and pharmaceutical collaborations with @AstraZeneca, @bmsnews, and @TakedaPharma Thanks to @endpts for breaking our news. endpts.com/exclusive-astr…
United States Trends
- 1. Good Thursday 23,8 B posts
- 2. #ThursdayThoughts 2.845 posts
- 3. Hawk Tuah 52,4 B posts
- 4. Bitcoin 1,21 Mn posts
- 5. Bitcoin 1,21 Mn posts
- 6. Happy Friday Eve N/A
- 7. $SOLSHI N/A
- 8. #5Dic 1.810 posts
- 9. #ThursdayMotivation 2.215 posts
- 10. #thursdayvibes 2.306 posts
- 11. #Wordle1265 N/A
- 12. namjoon 73,1 B posts
- 13. Obamacare 13,8 B posts
- 14. Hama 131 B posts
- 15. YEONJUN MEN OF THE YEAR 30,1 B posts
- 16. Toronto Tempo N/A
- 17. Coffeezilla 2.665 posts
- 18. Make Love 75 B posts
- 19. CEOs 52 B posts
- 20. Minato 12,6 B posts
Who to follow
-
Gleb Kuznetsov
@glebkuz -
Surge Biswas
@SurgeBiswas -
Subaita Rahman
@subaita_rahman -
Nabiha Saklayen
@nabsicle -
Jack O'Meara
@Jack_O_Meara -
Jake Becraft
@DrSynbio -
Dyno Therapeutics, Inc.
@Dyno_Tx -
Lexi Rovner
@lexrovner -
BigHat Biosciences
@BigHatBio -
Daniel Bryan Goodman
@dbgoodman -
Eric Kelsic (he/him)
@ekelsic -
omri_drory
@omri_drory -
Sean McClain
@SeanRMcClain -
Aviv Spinner
@AvivSpinner -
Nicolas Tilmans
@ntilmans
Something went wrong.
Something went wrong.